The Galectin 3 pipeline drugs market research report outlays comprehensive information on the Galectin 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Galectin 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Galectin 3 - Drugs In Development, 2024

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers products from therapy areas such as Oncology, Respiratory, Gastrointestinal, and Cardiovascular which include the indications Metastatic Melanoma, Recurrent Head And Neck Squamous Cell Carcinoma, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Arrhythmias, and Atrial Fibrillation. It also reviews key players involved in Galectin 3 targeted therapeutics development with respective active and dormant or discontinued products.

The Galectin 3 pipeline targets constitutes close to 12 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 2, 7, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Galectin 3 overview

Galectin-3 is a protein encoded by the LGALS3 gene. It mediates with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. It acts as a pre-mRNA splicing factor. It is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

For a complete picture of Galectin 3’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.